Plain-English translation of NCT06472713 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study tests a new treatment approach for nasopharyngeal carcinoma (cancer of the back of the nose and throat) that has returned or spread to other parts of the body after previous treatments. The trial combines with a type of immunotherapy drug called a PD-1 blockade. The goal is to see whether this combination can help patients whose cancer no longer responds to standard first-line treatments.
Many patients with nasopharyngeal cancer that has spread or returned find that their cancer stops responding to standard chemotherapy and immunotherapy treatments. This trial exists to test whether combining these two medications in a new way can help people who have already tried other treatments without success.
You likely qualify if…
You likely don't qualify if…
You would receive the combination medication (chemotherapy injection plus immunotherapy) every 3 weeks for up to 8 treatment cycles, followed by the immunotherapy drug alone once every 3 weeks for up to 2 years. Throughout the study, you will have regular clinic visits for blood tests and imaging scans to check how well the treatment is working and to monitor for any side effects. You will continue treatment until your cancer progresses, you experience unacceptable side effects, or the study ends.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China